FDA approves at-home use of Igalmi for agitation; deuterated psilocin meets phase 3 depression end point; lithium suicide evidence less certain

Listen to this post
read by AI voices · all episodesThe Food and Drug Administration (FDA) approved Teva's Igalmi sublingual dexmedetomidine for at-home use for agitation in schizophrenia and bipolar disorder, which Teva said makes it the first such treatment.
Helus Pharma reported that deuterated psilocin met its phase 3 primary end point in adjunctive treatment of depression. An umbrella review found lithium's effect on suicide less certain than earlier syntheses suggested.
- FDA Nov 16, 2026The Food and Drug Administration (FDA) approved Igalmi (dexmedetomidine) sublingual film for self-administration at home, or under health care provider supervision, for acute treatment of agitation associated with schizophrenia, schizoaffective disorder or bipolar disorder type I or type II in adults, Teva said Nov. 16, calling it the first FDA-approved at-home agitation treatment. In the phase 3 SERENITY At-Home trial, 1,160 agitation episodes in 102 patients were treated and the primary end point of safety and tolerability was met; the release reported no at-home efficacy results. The label warns of low blood pressure and slow heart rate.Sources: Teva, Psychiatric Times
- Research Nov 16, 2026Helus Pharma reported topline results from the phase 3 APPROACH trial of HLP003, a deuterated psilocin given on day 1 and three weeks later, added to stable antidepressants in 222 adults with moderate to severe major depressive disorder. At the primary end point at week 6, MADRS total score fell 19.5 points versus 11.9 with placebo (difference -7.6, P < .0001); remission was 50.9% versus 18.2%. There were three treatment-related serious adverse events, including a suicide attempt, according to Fierce Biotech. A second pivotal trial reports in the fourth quarter of 2027.Sources: Helus Pharma, Fierce Biotech
- Research Nov 18, 2026An umbrella review and meta-analysis in the American Journal of Psychiatry drew on randomized trials from 10 systematic reviews and one reanalysis, covering 3,675 participants in 20 trial publications. For completed suicide across 11 comparisons, the pooled estimate favored lithium but included the null (odds ratio 0.39, 95% CI 0.15 to 1.00). The authors concluded that current evidence indicates greater uncertainty than earlier syntheses suggested.Sources: American Journal of Psychiatry, PubMed
- Research Nov 19, 2026Open-label data from the phase 3 ADEPT-1 and ADEPT-3 studies of xanomeline and trospium chloride (KarXT) in Alzheimer disease psychosis were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, held Nov. 16 to 19 in Boston, Psychiatric Times reported Nov. 19. In ADEPT-1, 273 of 320 participants (85.3%) completed the 12-week open-label lead-in; in the 52-week open-label extension ADEPT-3, treatment-emergent adverse events occurred in 65.1% and serious ones in 7.7%. The findings are descriptive, and the double-blind data, including ADEPT-1's primary end point of time to relapse, remain blinded.
- Policy Nov 16, 2026The Department of Health and Human Services (HHS) Office for Civil Rights issued a final rule Nov. 16 modifying the HIPAA Privacy Rule. It cuts the time to respond to patient requests for record copies from 30 calendar days to 15, Healthcare Dive reported, and establishes a right to receive electronic records through a personal health app, amends access fees and reduces identity verification burdens, according to HHS. It also permits disclosures to social services agencies and community-based organizations. The rule takes effect 60 days after publication, with compliance due 180 days after that, Healio reported.
The weekly innovation roundup for psychiatry, published every Sunday for the week before; every item links to its sources. Latest psychiatry news · All specialties